Potassium News and Research

RSS

EDNOS categorization for young people needs to be reconsidered

Diagnostic cutoffs for anorexia nervosa and bulimia nervosa may be too strict, a study from the Stanford University School of Medicine and Lucile Packard Children's Hospital has found. Many patients who do not meet full criteria for these diseases are nevertheless quite ill, and the diagnosis they now receive, "Eating Disorder Not Otherwise Specified," may delay their ability to get treatment.

12 Apr 2010

Renal specialist says Dr Patel’s patient was too frail for surgery

In the ongoing trial of Dr Jayant Patel, Dr Peter Miach, a renal specialist, gave evidence before the Supreme Court in Brisbane. Dr Miach said the patient James Phillips had too many other problems and he would not have recommended surgery for him in his frail state.

12 Apr 2010

Blood levels of carbon dioxide may be linked to near death experiences after heart attack

Near death experiences have often been described as “seeing life flash before one’s eyes” or “intense feelings of joy and peace.” Now researchers claim that levels of Carbon Dioxide or CO2 may be the causal link for these sensations. They believe that the CO2 alters the levels of certain chemicals in the brain and makes it see lights at the ends of tunnels or dead loved ones.

9 Apr 2010

FDA approves Mylan Pharmaceuticals' generic NuLytely laxative

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution (with Flavor Packs), the generic version of Braintree Laboratories' NuLytely® laxative.

8 Apr 2010

FDA grants final approval for Teva Pharmaceutical Industries' generic Hyzaar and Cozaar

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

8 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

New report assesses optimal future for REMS

Two years after the Food and Drug Administration Amendments Act of 2007 gave FDA new powers to require Risk Evaluation and Mitigation Strategies for higher risk drugs and biologics, a new report concludes that an optimal future for REMS is possible if the agency adopts a systems approach when designing REMS programs and takes advantage of new technologies -- from electronic medical records to genetic testing -- that are changing the way medicine is practiced.

5 Apr 2010

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced that it has signed a co-promotion agreement for Zipsor™ (diclofenac potassium) Liquid Filled Capsules with Ferring Pharmaceuticals Inc., a global bio-pharmaceutical company, headquartered in Switzerland.

1 Apr 2010

Research could pave way for new generation of painkillers

An international group of scientists led by Dr Nikita Gamper of the University's Faculty of Biological Sciences has discovered how two proteins play a key role in the way we feel pain, offering new targets on which drug development can be focused.

25 Mar 2010

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

25 Mar 2010

Adrenal fatigue: Vitamins, supplements may do more harm than good

Taking vitamins or supplements to treat “adrenal fatigue” may do more harm than good, says Todd Nippoldt, M.D., a Mayo Clinic expert in hormone disorders affecting the adrenal glands.

23 Mar 2010

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Acorda Therapeutics, Inc. today announced that the Company has submitted applications to extend patent protection for AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg to the United States Patent and Trademark Office.

22 Mar 2010

Taking dietary supplements for adrenal fatigue may do more harm than good

Taking vitamins or supplements to treat "adrenal fatigue" may do more harm than good, says Todd Nippoldt, M.D., a Mayo Clinic expert in hormone disorders affecting the adrenal glands.

18 Mar 2010

Positive results from Phase IIa epilepsy study of ICA-105665

Icagen, Inc. today reported positive results in its Phase IIa epilepsy study of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist.

16 Mar 2010

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

15 Mar 2010

Study uncovers mechanism facilitating motivation for alcohol after extended abstinence

New research provides exciting insight into the molecular mechanisms associated with addiction and relapse. The study, published by Cell Press in the March 11 issue of the journal Neuron, uncovers a crucial mechanism that facilitates motivation for alcohol after extended abstinence and opens new avenues for potential therapeutic intervention.

11 Mar 2010

Review suggests ion exchange resins are not effective for hyperkalemia

For more than half a century, products containing ion exchange resins have been used in patients with dangerously high levels of potassium. However, there is no convincing evidence that these products are actually effective, according to an article appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

10 Mar 2010

Teens who drink 100% fruit juice have lower intakes of dietary fat and higher intakes of nutrients

New research published in the March/April issue of the American Journal of Health Promotion shows that teens who drink 100 percent fruit juice have more nutritious diets overall compared to non-consumers.

4 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Generic Hyzaar and Cozaar litigation: Court of Appeals rules in favor of Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva’s favor by overturning a July 31, 2009, district court decision which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

2 Mar 2010